Humasis Co

Humasis Co Change in Working Capital

The Change in Working Capital of Humasis Co (205470.KQ) as of Nov 10, 2026 is 15.13 B KRW. In the previous year, Change in Working Capital was 40.19 B KRW — a change of -62.36% (lower).

Change in Working Capital

15.13 BKRW

YoY

-62.36%

Last updated:

Change in Working Capital of Humasis Co is 2025 15.13 B KRW. Change in Working Capital of Humasis Co was 2024 40.19 B KRW. It decreases by -62.36% lower compared to the previous year.

The Humasis Co Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
-591.18 M KRW
Jan 1, 2019
-30.13 M KRW
Jan 1, 2020
-12.53 B KRW
Jan 1, 2021
7.82 B KRW
Jan 1, 2022
-60.56 B KRW
Jan 1, 2023
17.62 B KRW
Jan 1, 2024
40.19 B KRW
Jan 1, 2025
15.13 B KRW
The Humasis Co Change in Working Capital history
YEARChange in Working CapitalYoY
15.13 BKRW-62.36%
40.19 BKRW+128.09%
17.62 BKRW-129.10%
-60.56 BKRW-874.02%
7.82 BKRW-162.47%
-12.53 BKRW+41,473.16%
-30.13 MKRW-94.90%
-591.18 MKRW-37.94%
-952.56 MKRW-586.44%
195.82 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Change in Working Capital of Humasis Co is 15.13 B KRW in 2025.

Change in Working Capital of Humasis Co changed from 40.19 B KRW to 15.13 B KRW, representing a -62.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Humasis Co

All Key Metrics — Humasis Co